Little is known about the preferences of people with rheumatoid arthritis (RA) regarding tapering of biologic disease-modifying antirheumatic drugs (bDMARDs). The aim of this study was to assess the preferences of people with RA in relation to potential treatment- related benefits and risks of bDMARD tapering and the healthcare service-related attributes that affect tapering.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: